Disclosure: We earn commissions on purchases made through our links. This never influences our scores. Editorial policy
EPA Fish Oil
Omega-3 EPA has some of the strongest clinical evidence of any supplement for heart health.
- Evidence
- Strong Evidence
- Category
- Omega Fatty Acids
- Best form
- Re-esterified Triglyceride (rTG) - superior absorption
- Effective dose
- 2,000-4,000 mg of EPA daily
- Lab tested
- 5 of 10 products
- Category
- Omega Fatty Acids
- Best form
- Re-esterified Triglyceride (rTG) - superior absorption
- Effective dose
- 2,000-4,000 mg of EPA daily
- Lab tested
- 5 of 10 products
What Is EPA Fish Oil?
Omega-3 EPA has some of the strongest clinical evidence of any supplement for heart health. The REDUCE-IT trial (n=8,179 statin-treated patients with elevated triglycerides) showed that 4g/day of purified EPA (icosapent ethyl) reduced the primary composite endpoint by 25% (HR 0.75, 95% CI 0.68-0.83, p<0.001) and the key secondary endpoint (CV death + nonfatal MI + nonfatal stroke) by 26% (HR 0.74, p<0.0001). Total ischemic events (first + recurrent) were reduced by 30% (rate ratio 0.70, 61 vs 89 per 1,000 patient-years). The NNT was 21 over 4.9 years - meaning for every 21 high-risk patients treated, one major cardiovascular event was prevented.
The larger Japanese JELIS trial (n=18,645) confirmed that 1.8g/day EPA added to statin therapy significantly reduces coronary events. A 2021 meta-analysis (Khan et al., PMID: 34505026) quantified the EPA-specific advantage: pure EPA reduced CV mortality by 18% (RR 0.82, 95% CI 0.68-0.99), nonfatal MI by 28% (RR 0.72, 95% CI 0.62-0.84), and total coronary events by 27%. By contrast, EPA+DHA combination barely moved CV mortality (RR 0.94) or MI (RR 0.92) - a critical distinction.
The STRENGTH trial (n=13,078) tested 4g/day of EPA+DHA carboxylic acids (Epanova) against corn oil. Result: HR 0.99 (95% CI 0.90-1.09, p=0.84) - terminated early for futility. Every individual component was null. Even patients in the highest tertile of EPA levels showed no benefit. This trial is the strongest evidence that EPA alone drives the cardiovascular benefit, not omega-3s in general. The emerging biochemical hypothesis is that DHA competes with EPA at the cellular level - EPA's anti-inflammatory and membrane-stabilizing effects appear to require high selectivity, and DHA's competing metabolic pathways may reduce EPA's cardiovascular benefit when the two are co-administered at high doses. This explains why JELIS (pure EPA) and REDUCE-IT (pure EPA) succeeded while STRENGTH (EPA+DHA) failed completely.
A pharmacokinetic threshold appears to explain much of the discrepancy between trials. REDUCE-IT achieved median EPA plasma levels of 144.0 μg/mL at 1 year (up ~400% from baseline). STRENGTH achieved average peak EPA of only 89.6 μg/mL despite using similar doses - likely due to formulation differences in bioavailability. Even STRENGTH patients in the highest EPA tertile (>116 μg/mL) showed no cardiovascular benefit, suggesting the threshold for plaque stabilization and endothelial protection may require sustained EPA levels above what EPA+DHA combinations achieve. EPA plasma levels showed a strong inverse correlation with ischemic endpoints in REDUCE-IT.
An important caveat about REDUCE-IT: the mineral oil placebo was not biologically inert - hs-CRP increased >30%, LDL-C rose slightly, and ApoB increased significantly in the control arm. Modeling suggests the "true" HR may be closer to 0.88 rather than 0.75. However, even the adjusted estimate still represents a clinically meaningful 13%+ relative risk reduction attributable to pure EPA beyond lipid changes.
For triglyceride reduction, the AHA confirms that 2-4g daily of EPA effectively lowers triglycerides by 20-30% in moderate hypertriglyceridemia (200-499 mg/dL). Dose-response data show that 0.85g/day failed to alter TG, while 3.4g/day achieved 27% reduction (p=0.002) - there is a clear dose threshold for efficacy.
The form of omega-3 matters for absorption. Triglyceride (TG) and re-esterified triglyceride (rTG) forms absorb substantially better than ethyl ester (EE), especially without a fatty meal. However, the major cardiovascular trials used the ethyl ester form. For general supplementation, rTG is preferred for bioavailability. High-dose EPA therapy for cardiovascular risk should be guided by a physician.
Critical safety data at high doses: the Khan meta-analysis found EPA monotherapy uniquely increases bleeding risk (RR 1.49, 95% CI 1.20-1.84) - this was not seen with EPA+DHA combinations. Atrial fibrillation risk is elevated across all omega-3 formulations (RR 1.26, 95% CI 1.08-1.48), with EPA alone showing the highest signal (RR 1.35, 95% CI 1.10-1.66). An important advantage of pure EPA over EPA+DHA: high-dose EPA does not raise LDL-C, while EPA+DHA combinations increase LDL by 5-20% in patients with severe hypertriglyceridemia.
Does It Work? The Evidence
Reduces major adverse cardiovascular events in high-risk patients
SupportedREDUCE-IT trial (PMID: 30415628, n=8,179 statin-treated patients, 70.7% established ASCVD, 59% diabetes, median TG 216 mg/dL): 4g/day icosapent ethyl - primary composite endpoint HR 0.75 (95% CI 0.68-0.83, NNT=21). Individual components: fatal or nonfatal MI reduced 8.7% to 6.1% (p<0.001); STEMI 3.9% to 2.7% (p=0.0008); coronary revascularization 7.8% to 5.3% (p<0.001); CV death 5.2% to 4.3%. Key secondary endpoint reduced 26% (HR 0.74). Total ischemic events (first + recurrent) reduced 30% (rate ratio 0.70). Diabetic subgroup (n=4,787): primary endpoint reduced from 29.2% to 22.2% (p<0.0001). Prior MI subgroup (n=3,693): HR 0.74 (p=0.00001). US sub-cohort (n=3,146): HR 0.69 with NNT of 15 and 30% all-cause mortality reduction.
Reduces major coronary events in hypercholesterolemic patients
SupportedJELIS trial (PMID: 17398308, n=18,645): 1.8g/day EPA combined with statin therapy significantly reduced major coronary events
Lowers fasting triglyceride levels
SupportedAHA Science Advisory (PMID: 31422671): 2-4g daily of EPA+DHA or EPA alone lowers triglycerides by 20-30% in moderate hypertriglyceridemia (200-499 mg/dL); effect is dose-dependent. Dose-response data: 0.85g/day failed to alter TG; 3.4g/day achieved 27% reduction (p=0.002). In severe hypertriglyceridemia (≥500 mg/dL), reductions of 25-45% at 4g/day; in extreme cases (mean TG ~900 mg/dL), >60% reduction that dramatically lowers acute pancreatitis risk. Mechanism: EPA inhibits SREBP-1c (suppresses hepatic lipogenesis), activates PPAR-alpha (stimulates beta-oxidation), inhibits diacylglycerol acyltransferase, and increases LPL activity.
EPA monotherapy superiority over EPA+DHA for cardiovascular outcomes
SupportedKhan 2021 meta-analysis (PMID: 34505026, 38 RCTs, n=149,051): EPA monotherapy reduced CV mortality 18% (RR 0.82, 95% CI 0.68-0.99), nonfatal MI 28% (RR 0.72, 95% CI 0.62-0.84), total coronary events 27%. EPA+DHA combination: CV mortality RR 0.94, MI RR 0.92 - not significant. STRENGTH trial (PMID: 33190147, n=13,078, median TG 240 mg/dL, ~70% with diabetes, ~56% with established ASCVD): 4g/day EPA+DHA carboxylic acids vs corn oil terminated for futility. Individual endpoints: CV death HR 1.09 (p=0.37); nonfatal MI HR 0.97 (p=0.77); nonfatal stroke HR 1.14 (p=0.28); revascularization HR 0.94 (p=0.41). Core MACE: 9.4% vs 9.4% (HR 0.91, 95% CI 0.81-1.02). STRENGTH achieved peak EPA plasma levels of only 89.6 μg/mL vs REDUCE-IT's 144.0 μg/mL - a key pharmacokinetic difference.
Cardiovascular event reduction with EPA+DHA combination supplementation
IneffectiveSTRENGTH trial (PMID: 33190147, n=13,078): 4g/day EPA+DHA carboxylic acids vs corn oil terminated for futility (HR 0.99, 95% CI 0.90-1.09, p=0.84). Every individual endpoint null. Khan 2021 meta-analysis (PMID: 34505026, 38 RCTs, n=149,051): EPA+DHA combinations - CV mortality RR 0.94, MI RR 0.92, neither significant. Even patients in the highest tertile of EPA levels in STRENGTH showed no benefit.
Elevated atrial fibrillation risk at pharmacological doses (≥2g/day)
SupportedREDUCE-IT (PMID: 30415628): AFib hospitalization 5.3% vs 3.9% (EPA vs placebo). STRENGTH (PMID: 33190147): EPA+DHA AFib HR 1.69 (95% CI 1.29-2.21, NNH=114). Khan 2021 meta-analysis (PMID: 34505026): all omega-3 formulations RR 1.26 (95% CI 1.08-1.48); EPA alone RR 1.35 (95% CI 1.10-1.66). Risk appears dose-dependent and has not been consistently observed at standard supplemental doses (1-2g/day).
Reduces acute pancreatitis risk in severe hypertriglyceridemia (≥500 mg/dL)
Early SignalAHA Science Advisory (PMID: 31422671): at 4g/day in severe hypertriglyceridemia (≥500 mg/dL), TG reductions of 25-45%; in extreme cohorts (mean TG ~900 mg/dL), reductions exceeding 60% that substantially lower acute pancreatitis risk. Evidence is mechanistic and observational rather than from dedicated pancreatitis RCTs. Both EPA and EPA+DHA are effective for this indication - the MACE controversy does not affect the triglyceride-lowering evidence base.
| Claimed Benefit | Key Studies | Our Verdict |
|---|---|---|
| Reduces major adverse cardiovascular events in high-risk patients | REDUCE-IT trial (PMID: 30415628, n=8,179 statin-treated patients, 70.7% established ASCVD, 59% diabetes, median TG 216 mg/dL): 4g/day icosapent ethyl - primary composite endpoint HR 0.75 (95% CI 0.68-0.83, NNT=21). Individual components: fatal or nonfatal MI reduced 8.7% to 6.1% (p<0.001); STEMI 3.9% to 2.7% (p=0.0008); coronary revascularization 7.8% to 5.3% (p<0.001); CV death 5.2% to 4.3%. Key secondary endpoint reduced 26% (HR 0.74). Total ischemic events (first + recurrent) reduced 30% (rate ratio 0.70). Diabetic subgroup (n=4,787): primary endpoint reduced from 29.2% to 22.2% (p<0.0001). Prior MI subgroup (n=3,693): HR 0.74 (p=0.00001). US sub-cohort (n=3,146): HR 0.69 with NNT of 15 and 30% all-cause mortality reduction. | Supported |
| Reduces major coronary events in hypercholesterolemic patients | JELIS trial (PMID: 17398308, n=18,645): 1.8g/day EPA combined with statin therapy significantly reduced major coronary events | Supported |
| Lowers fasting triglyceride levels | AHA Science Advisory (PMID: 31422671): 2-4g daily of EPA+DHA or EPA alone lowers triglycerides by 20-30% in moderate hypertriglyceridemia (200-499 mg/dL); effect is dose-dependent. Dose-response data: 0.85g/day failed to alter TG; 3.4g/day achieved 27% reduction (p=0.002). In severe hypertriglyceridemia (≥500 mg/dL), reductions of 25-45% at 4g/day; in extreme cases (mean TG ~900 mg/dL), >60% reduction that dramatically lowers acute pancreatitis risk. Mechanism: EPA inhibits SREBP-1c (suppresses hepatic lipogenesis), activates PPAR-alpha (stimulates beta-oxidation), inhibits diacylglycerol acyltransferase, and increases LPL activity. | Supported |
| EPA monotherapy superiority over EPA+DHA for cardiovascular outcomes | Khan 2021 meta-analysis (PMID: 34505026, 38 RCTs, n=149,051): EPA monotherapy reduced CV mortality 18% (RR 0.82, 95% CI 0.68-0.99), nonfatal MI 28% (RR 0.72, 95% CI 0.62-0.84), total coronary events 27%. EPA+DHA combination: CV mortality RR 0.94, MI RR 0.92 - not significant. STRENGTH trial (PMID: 33190147, n=13,078, median TG 240 mg/dL, ~70% with diabetes, ~56% with established ASCVD): 4g/day EPA+DHA carboxylic acids vs corn oil terminated for futility. Individual endpoints: CV death HR 1.09 (p=0.37); nonfatal MI HR 0.97 (p=0.77); nonfatal stroke HR 1.14 (p=0.28); revascularization HR 0.94 (p=0.41). Core MACE: 9.4% vs 9.4% (HR 0.91, 95% CI 0.81-1.02). STRENGTH achieved peak EPA plasma levels of only 89.6 μg/mL vs REDUCE-IT's 144.0 μg/mL - a key pharmacokinetic difference. | Supported |
| Cardiovascular event reduction with EPA+DHA combination supplementation | STRENGTH trial (PMID: 33190147, n=13,078): 4g/day EPA+DHA carboxylic acids vs corn oil terminated for futility (HR 0.99, 95% CI 0.90-1.09, p=0.84). Every individual endpoint null. Khan 2021 meta-analysis (PMID: 34505026, 38 RCTs, n=149,051): EPA+DHA combinations - CV mortality RR 0.94, MI RR 0.92, neither significant. Even patients in the highest tertile of EPA levels in STRENGTH showed no benefit. | Ineffective |
| Elevated atrial fibrillation risk at pharmacological doses (≥2g/day) | REDUCE-IT (PMID: 30415628): AFib hospitalization 5.3% vs 3.9% (EPA vs placebo). STRENGTH (PMID: 33190147): EPA+DHA AFib HR 1.69 (95% CI 1.29-2.21, NNH=114). Khan 2021 meta-analysis (PMID: 34505026): all omega-3 formulations RR 1.26 (95% CI 1.08-1.48); EPA alone RR 1.35 (95% CI 1.10-1.66). Risk appears dose-dependent and has not been consistently observed at standard supplemental doses (1-2g/day). | Supported |
| Reduces acute pancreatitis risk in severe hypertriglyceridemia (≥500 mg/dL) | AHA Science Advisory (PMID: 31422671): at 4g/day in severe hypertriglyceridemia (≥500 mg/dL), TG reductions of 25-45%; in extreme cohorts (mean TG ~900 mg/dL), reductions exceeding 60% that substantially lower acute pancreatitis risk. Evidence is mechanistic and observational rather than from dedicated pancreatitis RCTs. Both EPA and EPA+DHA are effective for this indication - the MACE controversy does not affect the triglyceride-lowering evidence base. | Early Signal |
How to Choose: Forms, Doses & What Matters
Clinical dose: 2,000-4,000 mg of EPA daily; minimum effective dose for triglyceride lowering is 2,000 mg; major cardiovascular risk reduction requires 4,000 mg (REDUCE-IT protocol). Doses below 2,000 mg/day are insufficient for clinical management of hypertriglyceridemia.
Best forms: Re-esterified Triglyceride (rTG) - superior absorption, Triglyceride (TG) - good absorption, Phospholipids - good absorption
Take with a meal containing dietary fat to maximize absorption - this is especially critical for ethyl ester forms, which are poorly absorbed on an empty stomach. Split the dose into twice daily (e.g., morning and evening with meals) to reduce gastrointestinal side effects like nausea and fishy burps. Store softgels in a cool, dark place or refrigerate them to prevent oxidation and rancidity. Choose rTG or TG forms for general supplementation, as they offer superior absorption over ethyl esters.
Who Should Take EPA Fish Oil?
Individuals with elevated triglycerides (hypertriglyceridemia) seeking to lower cardiovascular risk. Patients at elevated cardiovascular risk despite statin therapy, particularly those who may qualify for high-dose EPA therapy under physician guidance. Those following clinical recommendations for secondary cardiovascular prevention.
Who Should Avoid It?
Individuals with a known allergy to fish or shellfish. Patients on anticoagulant or antiplatelet medications should not take high-dose EPA without medical supervision due to increased bleeding risk. Those highly prone to atrial fibrillation should exercise caution, as high-dose omega-3s (4 g/day or more) may slightly increase this risk. Anyone considering the REDUCE-IT-level dose (4 g/day) should do so only under physician guidance.
Side Effects & Safety
Fishy aftertaste or burps is the most common complaint - can be reduced by taking with meals, choosing enteric-coated softgels, or refrigerating capsules. Gastrointestinal tolerability differs significantly by formulation: pure EPA ethyl ester (REDUCE-IT) caused GI events comparable to the mineral oil placebo, but EPA+DHA carboxylic acid (Epanova, STRENGTH) caused substantially more GI distress - 24.7% vs 14.7% for any GI event; diarrhea 11.9% vs 4.9%. Arthralgia was the most common non-serious adverse event specific to pure EPA in REDUCE-IT. Oxidized fish oil is an underappreciated safety concern: OTC liquid fish oils can reach TOTOX values ~97 meq/kg and generic capsules ~30 meq/kg - reactive aldehydes from oxidized oil may induce systemic oxidative stress and negate cardiovascular benefits. Products with IFOS, NSF, or TOTOX certification are strongly preferred. Bleeding risk is uniquely elevated with EPA monotherapy (Khan meta-analysis: RR 1.49, 95% CI 1.20-1.84) - this was not seen with EPA+DHA combinations (STRENGTH: TIMI major bleeding 0.8% vs 0.7%). In REDUCE-IT, serious bleeding trended higher (2.7% vs 2.1%, p=0.06) but no increase in fatal bleeding or hemorrhagic stroke; this risk appears dose-dependent. Atrial fibrillation risk: REDUCE-IT showed AFib hospitalization at 5.3% vs 3.9%; STRENGTH showed HR 1.69 (95% CI 1.29-2.21, NNH=114); Khan meta-analysis: RR 1.35 (95% CI 1.10-1.66) for EPA alone. An advantage over EPA+DHA: pure EPA does not elevate LDL-C, whereas high-dose EPA+DHA combinations increase LDL by 5-20% in patients with severe hypertriglyceridemia.
Product Scores
10 products scored on dosing accuracy, third-party testing, cost per effective dose, and label transparency.
The Scorecard: 10 Products Compared
EPA Xtra
Nordic NaturalsHigh EPA:DHA ratio ideal for cardiovascular targeting, superior rTG absorption, and excellent reputation for low oxidation. Premium pricing is the tradeoff.
Prices checked 2026-03-31. Cost shown is per clinically effective daily dose, not per pill.
Triple Strength Omega 3 Fish Oil
Sports ResearchExcellent price per gram of EPA with IFOS 5-star certification and sustainable sourcing. Falls just short of the 1,000 mg clinical threshold per serving.
Prices checked 2026-03-31. Cost shown is per clinically effective daily dose, not per pill.
Ultra Pure Omega 3 Fish Oil Supplements
Omax Health
Very high EPA dose per serving with stringent NSF Sport certification and blister packaging to prevent oxidation. Uses ethyl ester form, which has lower absorption without fat.
Prices checked 2026-03-31. Cost shown is per clinically effective daily dose, not per pill.
Ultra Omega-3
NOW FoodsHighly affordable with enteric coating to prevent fishy burps. Uses the less bioavailable ethyl ester form - must take with a fatty meal for proper absorption.
Prices checked 2026-03-31. Cost shown is per clinically effective daily dose, not per pill.
Super EPA
ThorneHighest tier quality certification (NSF Sport) with CO2 extraction, but low EPA per serving makes it expensive for cardiovascular dosing
Prices checked 2026-03-31. Cost shown is per clinically effective daily dose, not per pill.
Omega 3 Fish Oil Supplements 3,000mg Per Serving
Micro Ingredients
High volume for a low price, but lacks third-party verification for rancidity (Totox values) and does not disclose the omega-3 form
Prices checked 2026-03-31. Cost shown is per clinically effective daily dose, not per pill.
Omega 3 Fish Oil 1200mg
Nature MadeUSP Verified for purity but fails on transparency by not disclosing the EPA/DHA split. Cannot be evaluated for cardiovascular EPA dosing.
Prices checked 2026-03-31. Cost shown is per clinically effective daily dose, not per pill.
EPA/DHA Essentials
Pure EncapsulationsRespected practitioner brand with clean formulation, but severely underdosed and extremely expensive per gram of EPA
Prices checked 2026-03-31. Cost shown is per clinically effective daily dose, not per pill.
Omega-3 Fish Oil 1000 mg
Spring ValleyGeneric unstandardized fish oil with no EPA/DHA breakdown, no third-party testing, and no verifiable GMP status. Extremely low price reflects the complete lack of quality assurance.
Prices checked 2026-03-31. Cost shown is per clinically effective daily dose, not per pill.
Fish Oil 1200mg Per Serving Softgels
Catfit
Deliberately hides EPA/DHA amounts while claiming the oil is 'rich' in them. Unknown brand with zero quality assurance. High risk of oxidized product. Avoid.
Prices checked 2026-03-31. Cost shown is per clinically effective daily dose, not per pill.
Full Comparison
| Category | EPA Xtra Nordic Naturals | Triple Strength Omega 3 Fish Oil Sports Research | Ultra Pure Omega 3 Fish Oil Supplements Omax Health | Ultra Omega-3 NOW Foods | Super EPA Thorne | Omega 3 Fish Oil Supplements 3,000mg Per Serving Micro Ingredients | Omega 3 Fish Oil 1200mg Nature Made | EPA/DHA Essentials Pure Encapsulations | Omega-3 Fish Oil 1000 mg Spring Valley | Fish Oil 1200mg Per Serving Softgels Catfit |
|---|---|---|---|---|---|---|---|---|---|---|
| Brand Score | 80/100Winner | 79/100 | 74/100 | 73/100 | 67/100 | 59/100 | 53/100 | 52/100 | 37/100 | 32/100 |
| Dosing & Form | 25/25Winner | 18/25 | 21/25 | 14/25 | 14/25 | 14/25 | 21/25 | 14/25 | 21/25 | 21/25 |
| Purity | 19/25 | 19/25 | 23/25Winner | 13/25 | 23/25 | 7/25 | 23/25 | 13/25 | 7/25 | 7/25 |
| Value | 13/25 | 19/25 | 7/25 | 23/25Winner | 7/25 | 19/25 | 2/25 | 2/25 | 2/25 | 2/25 |
| Transparency | 23/25Winner | 23/25 | 23/25 | 23/25 | 23/25 | 19/25 | 7/25 | 23/25 | 7/25 | 2/25 |
| Cost/Day | $0.78 | $0.45 | $1.10 | $0.36 | $1.07 | $0.55 | $0.00Winner | $1.78 | $0.00 | $0.00 |
| Dose/Serving | 1060mg | 690mg | 1510mg | 500mg | 425mg | 540mg | 1200mg (total fish oil) | 300mg | 1000mg (total fish oil) | 1200mg (total fish oil) |
| Form | Re-esterified Triglyceride (rTG) | Triglyceride (rTG) | Ethyl Ester | Ethyl Ester | Triglyceride | Unspecified | Unstandardized Fish Oil | Triglyceride | Unstandardized Fish Oil | Unstandardized Fish Oil |
| Third-Party Tested | ✓ Yes | ✓ Yes | ✓ Yes | No | ✓ Yes | No | ✓ Yes | No | No | No |
| Proprietary Blend | No | No | No | No | No | No | Yes | No | Yes | Yes |
Frequently Asked Questions
What is the difference between EPA and DHA?
Both are omega-3 fatty acids from fish oil, but they have different clinical profiles. EPA is more strongly associated with cardiovascular benefits including triglyceride lowering and cardiovascular event reduction (REDUCE-IT, JELIS). DHA is more important for brain development and structural brain health. For targeted cardiovascular support, high-EPA products are preferred.
What form of omega-3 is best absorbed?
Re-esterified triglyceride (rTG) and natural triglyceride (TG) forms are substantially better absorbed than ethyl ester (EE) forms, particularly without a high-fat meal. If you take an ethyl ester product, always take it with a meal containing fat. The REDUCE-IT trial used an ethyl ester form (icosapent ethyl), so event reduction data comes from that form specifically.
How much EPA do I need per day?
The clinical evidence supports 1,000-4,000 mg of EPA daily depending on your goal. For general triglyceride lowering, 1,000-2,000 mg is effective. The REDUCE-IT trial used 4,000 mg for major cardiovascular event reduction in high-risk patients. Doses above 3,000 mg should be discussed with your physician due to increased bleeding risk.
Why are some fish oil products so much cheaper than others?
The biggest factors are EPA concentration per softgel, the omega-3 form (ethyl ester is cheapest to manufacture, rTG is most expensive), third-party testing for oxidation and heavy metals, and brand quality standards. Cheap fish oil may use unstandardized oil with undisclosed EPA/DHA amounts, and may have higher oxidation levels.
Should I worry about mercury in fish oil supplements?
Reputable fish oil supplements undergo molecular distillation that removes heavy metals including mercury. Products with third-party certifications (IFOS, NSF, USP) are verified for contaminant levels well below safety thresholds. The concern about mercury is more relevant for whole fish consumption than for refined fish oil supplements.
Can fish oil cause atrial fibrillation?
Yes, at high doses this is a real risk. REDUCE-IT showed AFib hospitalization at 5.3% vs 3.9% in the EPA vs placebo groups. STRENGTH (EPA+DHA) showed an even higher signal: HR 1.69 (95% CI 1.29-2.21), with a number needed to harm of 114. The Khan 2021 meta-analysis quantified the risk across trials: RR 1.35 (95% CI 1.10-1.66) for EPA alone, and RR 1.26 (95% CI 1.08-1.48) for all omega-3 formulations. At standard supplemental doses (1-2 g/day), this risk has not been consistently observed. Anyone with a history of or predisposition to AFib should consult their cardiologist before taking high-dose omega-3s.
Why do some products list total fish oil instead of EPA?
This is a transparency red flag. Total fish oil weight includes the glycerol backbone and other fatty acids, not just the active EPA and DHA. A 1,200 mg fish oil softgel may contain only 300-360 mg of total omega-3s, with the EPA/DHA split unknown. Always look for products that explicitly list EPA and DHA amounts separately.
Can OTC fish oil supplements replicate the REDUCE-IT results?
No. A standard 1,000mg fish oil capsule contains only about 180mg EPA, meaning you would need 22-23 capsules daily to reach the 4g EPA dose used in REDUCE-IT. Even premium concentrated products require 8-12 capsules daily. All OTC supplements also contain DHA, which may antagonize EPA's cardiovascular mechanisms based on the STRENGTH trial's null result with EPA+DHA. The 4g/day pure EPA dose used in REDUCE-IT is realistically only achievable through prescription icosapent ethyl (Vascepa). OTC EPA supplements at 1-2g/day may still provide meaningful triglyceride lowering but should not be expected to deliver the 25% cardiovascular event reduction seen in REDUCE-IT.
Does the mineral oil placebo in REDUCE-IT inflate the results?
Possibly to some degree. The mineral oil placebo was not biologically inert - hs-CRP increased over 30% and LDL-C rose slightly in the control arm. Modeling from the Copenhagen General Population Study estimated the 'true' HR may be closer to 0.88 rather than the reported 0.75. However, even the conservative adjusted estimate represents a clinically meaningful 12-13% relative risk reduction attributable to pure EPA beyond placebo effects. The JELIS trial, which used an open-label design without mineral oil, also showed significant benefit, corroborating that EPA's cardiovascular effects are real.
Related Articles
Scorecard Newsletter
New scores and research, weekly.
We publish new supplement scorecards and evidence summaries every week. No spam, no affiliate pitches - just the research.
Sources
- Bhatt DL, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT). N Engl J Med. 2019;380(1):11-22.
- Yokoyama M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090-8.
- Skulas-Ray AC, et al. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. Circulation. 2019;140(12):e673-e691.
- Khan SU, et al. Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis. EClinicalMedicine. 2021;38:100997.
- Nicholls SJ, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk (STRENGTH). JAMA. 2020;324(22):2268-2280.
- Bhatt DL, et al. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. J Am Coll Cardiol. 2019;73(22):2791-2802.
- Bhatt DL, et al. Icosapent ethyl in US REDUCE-IT patients: cardiovascular risk reduction and mortality benefit. Eur Heart J. 2022;43(suppl 2):ehac544.
- Bhatt DL, et al. Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial. Clin Cardiol. 2017;40(3):138-148.
- Skulas-Ray AC, et al. Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia. Am J Clin Nutr. 2011;93(2):243-252.
- Hilleman DE, Wiggins BS, Bottorff MB. Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review. Postgrad Med. 2020;132(1):7-12.
- Harris WS, et al. Fish oil - how does it reduce plasma triglycerides? Biochim Biophys Acta. 2012;1821(5):843-851.
- NIH Office of Dietary Supplements. Omega-3 Fatty Acids - Health Professional Fact Sheet.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. The products discussed on this page are not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before starting any supplement regimen.